Answers are grounded in this paper and cite their sources.
Personalized neoantigen vaccines promise precise cancer immunotherapy, yet identifying immunogenic epitopes remains challenging. This review evaluates bioinformatics and multi-omics pipelines across a four-tier framework: variant-to-candidate prediction, HLA binding and presentation, immunopeptidomics, and proteogenomic integration. We examine MHC-II modeling, long-read sequencing, and TCR-aware architectures while addressing biological bottlenecks, such as tumor heterogeneity and immune evasion, to accelerate the development and clinical translation of robust, personalized cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
Lerksuthirat et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: